Literature DB >> 30639908

Associations between repeated measure of plasma perfluoroalkyl substances and cardiometabolic risk factors.

Carolina Donat-Vargas1, Ingvar A Bergdahl2, Andreas Tornevi2, Maria Wennberg3, Johan Sommar2, Jani Koponen4, Hannu Kiviranta4, Agneta Åkesson5.   

Abstract

BACKGROUND: Perfluoroalkyl substances (PFAS) are persistent synthetic chemicals that may affect components of metabolic risk through the peroxisome proliferator-activated receptor but epidemiological data remain scarce and inconsistent.
OBJECTIVE: To estimate associations between repeated measurements of the main PFAS in plasma and total cholesterol, triglycerides and hypertension among the control subjects from a population-based nested case-control study on diabetes type 2 in middle-aged women and men.
METHODS: Participants (n = 187) were free of diabetes at both baseline and follow-up visits to the Västerbotten Intervention Programme, 10 years apart: during 1990 to 2003 (baseline) and 2001 to 2013 (follow-up). Participants left blood samples, completed questionnaires on diet and lifestyle factors, and underwent medical examinations, including measurement of blood pressure. PFAS and lipids were later determined in stored plasma samples. Associations for the repeated measurements were assessed using generalized estimating equations.
RESULTS: Six PFAS exceeded the limit of quantitation. Repeated measures of PFAS in plasma, cardiometabolic risk factors and confounders, showed an average decrease of triglycerides from -0.16 mmol/l (95% confidence interval [CI]: -0.33, 0.02 for PFOA) to -0.26 mmol/l (95% CI: -0.50, -0.08 for PFOS), when comparing the highest tertile of PFAS plasma levels with the lowest. Associations based on average PFAS measurements and follow-up triglycerides revealed similar inverse associations, although attenuated. The estimates for cholesterol and hypertension were inconsistent and with few exception non-significant.
CONCLUSIONS: This study found inverse associations between PFAS and triglycerides, but did not support any clear link with either cholesterol or hypertension.
Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Cardiometabolic risk factors; Environmental epidemiology; Hypertension; Lipids; Plasma perfluoroalkyl substances; Prospective assessment; Repeated measurements

Mesh:

Substances:

Year:  2019        PMID: 30639908     DOI: 10.1016/j.envint.2019.01.007

Source DB:  PubMed          Journal:  Environ Int        ISSN: 0160-4120            Impact factor:   9.621


  10 in total

1.  Per- and polyfluoroalkyl substances and blood lipid levels in pre-diabetic adults-longitudinal analysis of the diabetes prevention program outcomes study.

Authors:  Pi-I D Lin; Andres Cardenas; Russ Hauser; Diane R Gold; Ken P Kleinman; Marie-France Hivert; Abby F Fleisch; Antonia M Calafat; Thomas F Webster; Edward S Horton; Emily Oken
Journal:  Environ Int       Date:  2019-05-28       Impact factor: 9.621

Review 2.  Non-targeted metabolomics and associations with per- and polyfluoroalkyl substances (PFAS) exposure in humans: A scoping review.

Authors:  Pengfei Guo; Tristan Furnary; Vasilis Vasiliou; Qi Yan; Kate Nyhan; Dean P Jones; Caroline H Johnson; Zeyan Liew
Journal:  Environ Int       Date:  2022-02-26       Impact factor: 9.621

3.  Per- and Polyfluoroalkyl Substances and Incident Hypertension in Multi-Racial/Ethnic Women: The Study of Women's Health Across the Nation.

Authors:  Ning Ding; Carrie A Karvonen-Gutierrez; Bhramar Mukherjee; Antonia M Calafat; Siobán D Harlow; Sung Kyun Park
Journal:  Hypertension       Date:  2022-06-13       Impact factor: 9.897

4.  Per- and polyfluoroalkyl substances and blood pressure in pre-diabetic adults-cross-sectional and longitudinal analyses of the diabetes prevention program outcomes study.

Authors:  Pi-I D Lin; Andres Cardenas; Russ Hauser; Diane R Gold; Ken P Kleinman; Marie-France Hivert; Antonia M Calafat; Thomas F Webster; Edward S Horton; Emily Oken
Journal:  Environ Int       Date:  2020-02-20       Impact factor: 9.621

Review 5.  Exposure to Perfluoroalkyl Chemicals and Cardiovascular Disease: Experimental and Epidemiological Evidence.

Authors:  Alessandra Meneguzzi; Cristiano Fava; Marco Castelli; Pietro Minuz
Journal:  Front Endocrinol (Lausanne)       Date:  2021-07-09       Impact factor: 5.555

6.  Associations of Perfluoroalkyl substances with blood lipids and Apolipoproteins in lipoprotein subspecies: the POUNDS-lost study.

Authors:  Gang Liu; Bo Zhang; Yang Hu; Jennifer Rood; Liming Liang; Lu Qi; George A Bray; Lilian DeJonge; Brent Coull; Philippe Grandjean; Jeremy D Furtado; Qi Sun
Journal:  Environ Health       Date:  2020-01-13       Impact factor: 5.984

7.  Associations of Perfluoroalkyl Substances with Prevalence of Metabolic Syndrome in Highly Exposed Young Adult Community Residents-A Cross-Sectional Study in Veneto Region, Italy.

Authors:  Maryam Zare Jeddi; Teresa Dalla Zuanna; Giulia Barbieri; Aline S C Fabricio; Francesca Daprà; Tony Fletcher; Francesca Russo; Gisella Pitter; Cristina Canova
Journal:  Int J Environ Res Public Health       Date:  2021-01-29       Impact factor: 3.390

8.  Serum concentrations of legacy and emerging per- and polyfluoroalkyl substances in the Anniston Community Health Surveys (ACHS I and ACHS II).

Authors:  Michael C Petriello; M Abdul Mottaleb; Tara C Serio; Bharat Balyan; Matthew C Cave; Marian Pavuk; Linda S Birnbaum; Andrew J Morris
Journal:  Environ Int       Date:  2021-11-08       Impact factor: 13.352

9.  Pregnancy Per- and Polyfluoroalkyl Substance Concentrations and Postpartum Health in Project Viva: A Prospective Cohort.

Authors:  Susanna D Mitro; Sharon K Sagiv; Abby F Fleisch; Lindsay M Jaacks; Paige L Williams; Sheryl L Rifas-Shiman; Antonia M Calafat; Marie-France Hivert; Emily Oken; Tamarra M James-Todd
Journal:  J Clin Endocrinol Metab       Date:  2020-09-01       Impact factor: 5.958

10.  Co-exposure to PCB126 and PFOS increases biomarkers associated with cardiovascular disease risk and liver injury in mice.

Authors:  Pan Deng; Chunyan Wang; Banrida Wahlang; Travis Sexton; Andrew J Morris; Bernhard Hennig
Journal:  Toxicol Appl Pharmacol       Date:  2020-10-20       Impact factor: 4.219

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.